BioWorld

Feb. 13, 2009

Portola's Anticlotting Drug Gains Partner in Potential $575M Deal

In its first major collaboration, privately held Portola Pharmaceuticals Inc. partnered one of its two lead antithrombotic programs with Novartis AG in a deal potentially worth up to $575 million. (BioWorld Today) Read More

Futility Analysis Derails BioMarin and LJP's Phase III Riquent Trial

Better Blood Supply Leads to Better-Behaved Tumors

Insmed Jumps on Merck $130M Bid for FOBs Drugs

Holiday Notice

Corrections & Clarifications

Alios Closes $8.4M Tranche of $24M Series A Round

Oscient and Telik Cut Deep to Conserve Capital

Novelos, Mundipharma Sign $95M Deal for Cancer Drug

Appointments And Advancements

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

US lawmakers demand that Kennedy be held accountable

BioWorld

As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...